Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365563 | 0.84 | KMT2A (0.37) | SIRT2KDM4EKMT2APOLBRAB9A | |
| SCHEMBL19365723 | 0.80 | DYRK1A (0.38) | ABL1KMT2AGSK3BDYRK1AFAAH | |
| SCHEMBL19365318 | 0.80 | ALOX15 (0.46) | SIRT2MAPTGSK3BDYRK1AFAAH | |
| SCHEMBL19365767 | 0.80 | SIRT2 (0.36) | SIRT2ABL1GSK3BDYRK1AFAAH | |
| SCHEMBL19670235 | 0.79 | GSK3B (0.36) | SIRT2ABL1KDM4EKMT2APOLB | |
| SCHEMBL19706220 | 0.79 | MAP3K5 (0.35) | KDM4ERAB9AGSK3BDYRK1AFAAH | |
| SCHEMBL17618678 | 0.78 | KMO (0.36) | SIRT2ABL1KDM4EKMT2APOLB | |
| SCHEMBL19706131 | 0.76 | POLB (0.42) | SIRT2KDM4EKMT2APOLBRAB9A | |
| SCHEMBL19670621 | 0.76 | SIRT2 (0.36) | SIRT2ABL1KMT2AMEN1GSK3B | |
| SCHEMBL19670416 | 0.75 | GRM5 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SIRT2 3/4885ABL1 4089/4885KDM4E 950/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | SIRT2 3/4885ABL1 4089/4885KDM4E 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.